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Abstract
Mortality rates for severe community-acquired pneumonia (CAP) range from 17 to 48 % in published studies.
In this review, we searched PubMed for relevant papers published between 1981 and June 2016 and relevant files.
We explored how early and aggressive management measures, implemented within 24 hours of recognition of
severe CAP and carried out both in the emergency department and in the ICU, decrease mortality in severe CAP.
These measures begin with the use of severity assessment tools and the application of care bundles via clinical
decision support tools. The bundles include early guideline-concordant antibiotics including macrolides, early
haemodynamic support (lactate measurement, intravenous fluids, and vasopressors), and early respiratory support
(high-flow nasal cannulae, lung-protective ventilation, prone positioning, and neuromuscular blockade for acute
respiratory distress syndrome).
While the proposed interventions appear straightforward, multiple barriers to their implementation exist.
To successfully decrease mortality for severe CAP, early and close collaboration between emergency medicine
and respiratory and critical care medicine teams is required. We propose a workflow incorporating these
interventions.
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Background
Community-acquired pneumonia (CAP) has plagued
humankind for millennia. Hippocrates described pneu-
monia as a disease which the “ancients” named, and
stated that “when pneumonia is at its height, the case is
beyond remedy if he is not purged” [1]. Prognosis
remained bleak through the centuries. Osler, widely
recognised as the father of modern medicine, called
pneumonia the “captain of the men of death” in 1901
[2]. Although outcomes improved with the advent of
antibiotics, CAP continues to be one of the world’s leading
causes of hospitalisation, morbidity, and mortality [3, 4].
Studies have shown that between 2 and 24 % of patients
presenting to hospitals with CAP require admission to an
ICU [5–7]. Hospital mortality rates for these patients
range from 17 to 49 % in large multicentre cohort studies
[8–10], and there are conflicting data on whether these
rates are increasing or decreasing over time [11, 12].
Calls have been made to treat CAP as an emergency,
with aggressive interventions to lower mortality [13].
Unfortunately, while national and international clinical
practice guidelines for CAP typically review severity as-
sessment, diagnostic tools, and choice of antibiotics, they
do not emphasise the importance of timely resuscitation
and care of respiratory failure [14–17]. In this review, we
will explore how early and aggressive management mea-
sures may result in decreased mortality in severe CAP.
We focus on the impact of management measures im-
plemented within the first 24 hours and carried out both
in the emergency department (ED) and in the ICU.
These measures comprise those which specifically target
severe CAP, such as identification and antibiotics, as well
as those which target its complications, including septic
shock and respiratory failure.
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Methods
We electronically searched PubMed (1981–June 2016)
using a sensitive search strategy without language re-
strictions and with the following Medical Subject Head-
ings (MeSH®) terms: “pneumonia”, “mortality”, “severe”,
“severity assessment tools”, “severity scores”, “emergency
service, hospital”, and “intensive care units”, “antibi-
otics”, “sepsis”, “shock septic”, “resuscitation”, “early
goal-directed therapy”, “hypoxaemia”, “acute respiratory
distress syndrome”, “patient care bundles”, and “quality
improvement”. We supplemented the search by review-
ing references of included studies and our files. The
findings of key papers on the impact of various manage-
ment measures on mortality are summarised in Table 1.
For key studies on sepsis and respiratory failure which
also enrolled patients without severe CAP, we recorded
the proportion of patients with pneumonia. We used the
principles of the Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) system to
assess the quality of evidence as high (well-done rando-
mised trials), moderate (downgraded randomised trials
or upgraded observational studies), low (well-done ob-
servational studies), or very low (downgraded observa-
tional studies) [18].
Early recognition of severe CAP
Severity assessment tools may help clinicians recognise
severe CAP and select patients for early intervention. In
1997, Fine et al. [19] showed that the Pneumonia Sever-
ity Index (PSI) predicts mortality. This was followed by
validation of the CURB65 (Confusion, Urea, Respiratory
Rate, Blood pressure, Age > 65 years) score [20]. How-
ever, while both the PSI and the CURB65 score guide
decisions to hospitalise patients, they were not designed to
guide ICU admission. After two earlier iterations [21, 22],
the American Thoracic Society (ATS) and the Infectious
Diseases Society of America (IDSA) recommended a set of
major and minor criteria for ICU admission in 2007 [14].
The major criteria are invasive mechanical ventilation and/
or the need for vasopressors. Fulfilment of the minor
criteria requires three or more of the following: tachyp-
noea, hypoxaemia, multilobar infiltrates, confusion, urae-
mia, leukopaenia, thrombocytopaenia, hypothermia, and
hypotension. Several groups have validated these criteria
using existing pneumonia databases [23–26].
Two systematic reviews and meta-analyses found 40
studies on different severity assessment tools to guide
ICU admission [5, 6]. Marti et al. [5] found that the
2007 IDSA/ATS rule had a pooled sensitivity and speci-
ficity of 84 % and 78 % respectively for the prediction of
ICU admission, while Chalmers et al. [6] found a pooled
sensitivity and specificity of 61 % and 89 % respectively.
When the major criteria were removed from the rule,
the minor criteria had a pooled sensitivity and specificity
of 57 % and 90 % respectively according to Marti et al.
[5], and of 56 % and 92 % respectively according to
Chalmers et al. [6]. Other similar tools include the
SMART-COP (Systolic blood pressure, Multilobar infil-
trates, Albumin, Respiratory rate, Tachycardia, Confu-
sion, low Oxygen, low PH) which had a pooled
sensitivity and specificity of 79 % and 64 % respectively,
and the SCAP (Severe Community-Acquired Pneumo-
nia) score which had a pooled sensitivity and specificity
of 94 % and 46 % respectively [5].
Severity assessment tools have several limitations [13].
Firstly, they do not differentiate preventable mortality
(which may be reduced by timely management mea-
sures) and non-preventable mortality (such as in older
patients with multiple co-morbidities and do-not-
resuscitate orders), and evidence that adoption of these
tools may improve outcomes remains weak [27]. This
concern is partly mitigated by tools such as the IDSA/
ATS minor criteria, which do not contain age or co-
morbid illness factors and therefore select patients based
on acute physiology, as opposed to tools such as the PSI
[14, 19]. Secondly, studies of severity assessment tools
often did not exclude patients with orders to withhold
life-sustaining treatments, thus compromising the valid-
ity of their findings [5, 6]. Thirdly, because their sensitiv-
ity and specificity are not 100 %, some patients who
would have done well even without close monitoring
may be admitted to an already resource-limited ICU,
while others at risk for death would not be detected
[5, 6]. Fourthly, decisions for ICU admission are
dependent on local culture and resources [28]. Some
groups have used the need for mechanical ventilation
and vasoactive agents rather than ICU admission per
se as end points [29–31]. Fifthly, it remains to be
seen how these tools which are specifically for CAP
compare with more generic criteria for sepsis such as
the recently introduced quick Sequential Organ Failure
Assessment (qSOFA) score, which predicts poor outcomes
in the presence of at least two of the following: systolic
blood pressure ≤ 100 mmHg, respiratory rate ≥ 22/min, or
altered mentation [32].
Early action with or without ICU admission
Much work has been devoted to finding the ideal sever-
ity assessment tool to guide ICU admission because sev-
eral studies have linked delayed ICU admission for
severe CAP with increased mortality [33–36]. Such a
finding, however, does not necessarily mean that earlier
ICU admissions will result in improved survival. Some
patients are admitted late to the ICU because of subse-
quent deterioration and not because they are unwell to
begin with [37]. This notwithstanding, the adverse effect
on mortality of admitting patients from an ED to a gen-
eral ward rather than straight to an ICU persisted even
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Table 1 Early management measures and impact on mortality in severe community-acquired pneumonia and its complications
Intervention Patient population Number of
patients
Number with pneumoniaa Mortality
reduction
Mortality definition Risk (95 % CI) Evidence quality Selected
reference
CAP severity assessment
tools to guide management
Severe CAP in hospital 348 348 with CAP Yes Hospital Adjusted OR 0.24
(0.09–0.67)
Low; before-and-after study [27]
Guideline-concordant
antibiotics
CAP in hospital 1288 1288 with CAP Yes Hospital mortality Adjusted OR 0.55
(0.30–0.90)
Low; observational study [39]
Macrolide combination
treatment
Severe CAP in ICUs 8872 8872 with CAP Yes Hospital, ICU, 28-day
or 30-day
RR 0.84 (0.71–1.00) Moderate; systematic review
of observational studies
[48]
Early antibiotics within 1 hour Sepsis and septic
shock
11,017 Data not available Uncertain Hospital or 28-day OR 0.68 (0.42–1.12) Moderate; systematic review
of observational studies
[56]
Early antibiotics after septic
shock
Septic shock 2154 838 Yes Hospital Adjusted OR 0.89
(0.88–0.91)
per hour earlier
Low; observational study [55]
Early goal-directed therapy Septic shock 4201 1278 Uncertain 90-day OR 0.99 (0.86–1.15) High; systematic review of
RCTs
[66]
High-flow nasal cannula PaO2/FIO2≤ 300
mmHg
310 254 (197 with CAP) Yes 90-day HR 0.50 (0.25–0.99) High; RCT [71]









2299 1145 Yes Hospital Adjusted RR 0.90
(0.81–1.00)
Moderate; systematic review
of RCTs; conflicting results with
other systematic reviews
[79]
Low driving pressure ARDS with PaO2/FIO2
≤ 300 mmHg
3562 1314b Yes Hospital at 60 days RR 0.71 (0.66–0.76)
for each 1-SD decrease
in driving pressure
Moderate; systematic review
of RCTs of different objectives
and methods
[77]
Neuromuscular blockade ARDS with PaO2/FIO2
< 150 mmHg
339 262 (130 with CAP) Yes 90-day Adjusted HR 0.68
(0.48–0.98)
High; RCT [81]
Prone positioning ARDS with PaO2/FIO2
< 150 mmHg
466 281 Yes 28-day HR 0.39 (0.25–0.63) High; RCT [83]
Corticosteroids Severe CAP according
to severity assessment
tools
388 388 with CAP Uncertain Varies between
RCTs
RR 0.39 (0.20–0.77) Moderate; systematic review
of RCTs; conflicting results
with other systematic reviews
[87]
Care bundles CAP in hospital 2118 2118 with CAP Yes 30-day Adjusted OR 0.59
(0.37–0.95)
Low; before-and-after study [97]
aNumbers include all forms of pneumonia, including CAP and hospital-acquired pneumonia. Number of CAP patients is stated where available
bA total of 1314 out of 3449 patients had pneumonia (specific data on pneumonia were not available from one study of 113 patients [106])
CI confidence interval, OR odds ratio, RCT randomised controlled trial, PaO2 partial pressure of arterial oxygen, FIO2 fraction of inspired oxygen, HR hazard ratio, ARDS acute respiratory distress syndrome, RR risk ratio,









when accounting for late deteriorations by adding radio-
graphic progression to a logistic regression model [38].
Other patients are admitted to the ICU late because
clinicians may sometimes inadvertently underestimate
the severity of illness in the ED [38]. In these cases, earl-
ier ICU admission alone is insufficient, and must be
paired with aggressive management measures in the ED.
Indeed, patients in a Singaporean study deemed critically
ill and directly transferred from the ED to the ICU re-
ceived more fluids and antibiotics in the ED than those
triaged to the general wards and transferred to the ICU
later [35].
Given the limitations of severity assessment tools, we
argue that it is time to move on from the search for the
perfect tool to effective translation of currently available
tools into action. Lim et al. [27] linked CAP severity
assessment tools to management prior to initiation of
mechanical ventilation or vasopressors. Their multifa-
ceted intervention used the 2007 IDSA/ATS minor cri-
teria to identify severe CAP early in the ED and to
trigger empiric antibiotics within 3 hours of triage,
prompt intubation for respiratory failure, fluid resuscita-
tion, and vasopressors for patients with hypotension or
shock. This before-and-after study reported a decrease
in the hospital mortality rate from 24 % to 6 % (Table 1).
While inappropriately delayed ICU admissions decreased
from 32 % to 15 %, the intervention also decreased the
overall ICU admission rates from 53 % to 39 % because
early and appropriate resuscitative measures in the ED
helped to stabilise patients who could then be managed
on a general ward.
Early antimicrobial therapy
Common causative organisms for severe CAP include
Streptococcus pneumoniae, Staphylococcus aureus, Le-
gionella species, Gram-negative bacilli, Haemophilus
influenzae, and influenza A and B viruses [14, 15, 17].
Adherence to guidelines for empiric antibiotics is associ-
ated with improved survival [39, 40] (Table 1), although
microbial aetiology varies across time and place, and
different guidelines have proposed slightly different
antimicrobial regimes. In general, however, American,
British, and European guidelines all recommend em-
pirically starting a beta-lactam (such as amoxicillin-
clavulanate, ampicillin-sulbactam, cefotaxime, or cef-
triaxone) plus a macrolide (such as azithromycin or
clarithromycin) [14–17]. American and European
guidelines suggest that a fluoroquinolone (such as
levofloxacin or moxifloxacin) may be substituted for
the macrolide [14, 17].
Several systematic reviews which explored the role of
macrolides in CAP have arrived at different conclusions,
depending on the type of studies included. In general,
lower-quality observational studies tend to suggest
survival benefits [41, 42], as opposed to studies on non-
critically ill patients and randomised trials [43, 44]. Two
high-quality randomised trials were recently published: a
Dutch trial concluded that beta-lactam monotherapy
was non-inferior to beta-lactam plus macrolide combin-
ation for 90-day mortality [45], but a Swiss trial could
not demonstrate non-inferiority [46]. While these trials
included non-ICU patients, macrolides have immune-
modulatory effects in addition to antimicrobial proper-
ties which may benefit sicker and more septic patients
[47]. Indeed, in a systematic review of 25 observational
studies of 8872 patients with severe CAP, combination
treatment with macrolides was associated with lower
mortality compared with treatment without macrolides,
including when guideline-concordant regimens of beta-
lactam/macrolide and beta-lactam/fluoroquinolone were
specifically compared [48] (Table 1).
Multidrug resistance is increasingly of concern, and
American and European guidelines also suggest that
when a Pseudomonas infection is suspected, the beta-
lactam used should have antipseudomonal effects (such
as piperacillin-tazobactam, cefepime, imipenem, or mer-
openem) [14, 17]. In addition, the IDSA/ATS recom-
mended in 2005 [49] that extended-spectrum antibiotics
should be used for patients admitted from the commu-
nity if they have risk factors for harbouring resistant
organisms, such as a recent hospitalisation, residence in
a nursing home or extended care facility, home infusion
therapy, chronic dialysis, home wound care, or a family
member with a multidrug-resistant pathogen. This
form of pneumonia was termed healthcare-associated
pneumonia (HCAP). Recent work, however, has
shown that the HCAP criteria poorly predict the
presence of resistant organisms, and that administra-
tion of broad-spectrum antibiotics based on these
criteria does not improve outcomes [50–52].
A recent systematic review concluded from four large
observational studies that administration of antibiotics
for CAP within 4–8 hours of hospital arrival was associ-
ated with a 5–43 % relative reduction in mortality, even
in non-ICU patients [41]. Multiple investigators have as-
sociated early administration of appropriate antibiotics
with improved survival in sepsis [53, 54]. Kumar et al.
[55] reported that each hour of delay in antibiotic ad-
ministration lowered survival by 8 % in septic shock
(838 out of 2154 patients had pneumonia) (Table 1).
However, a recent systematic review of 11 studies which
reported the time from recognition of sepsis or septic
shock to antibiotic administration did not find such an
association [56] (Table 1). The latter analysis, however,
must be interpreted with caution due to selection bias
from excluded studies, the lack of microbiological data,
and the lack of confidence that all patients studied had
bacterial sepsis [57]. The Surviving Sepsis Campaign
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recommends administering antibiotics within the first
hour of recognition of sepsis and septic shock, and the
same is prudent for severe CAP [54, 58].
Early haemodynamic support
Pneumonia is the most common cause of sepsis and
often presents with septic shock [59, 60]. In a recent
multicentre Spanish study, one-third of hospitalisations
for CAP were complicated by sepsis [61]. The Third
International Consensus Definitions for Sepsis and
Septic Shock (Sepsis-3) [32] state that patients with
septic shock can be identified clinically by a vasopressor
requirement to maintain a mean arterial pressure ≥ 65
mmHg, and a serum lactate level ≥ 2 mmol/L after
adequate fluid resuscitation, although some controversy
exists because most studies from which these criteria
were derived measured lactate upon presentation and
before fluids. In 2001, Rivers et al. [62] showed that a
protocol for haemodynamic optimisation known as early
goal-directed therapy (EGDT) decreased hospital mor-
tality in sepsis and septic shock from 46.5 % to 30.5 %.
The EGDT bundle included lactate measurement, fluid
resuscitation according to the central venous pressure,
vasoactive agents to keep the mean arterial pressure at
65–90 mmHg, and red blood cell transfusion and/or
inotropes according to the central venous oxygen satur-
ation. Pneumonia accounted for 39 % of the enrolled
patients and was the commonest cause of sepsis in the
study.
In 2014 and 2015, however, three large multicentre
randomised trials—the ProCESS, ARISE, and ProMISe
studies [63–66]—reported that EGDT was not superior
to usual care for ED patients with septic shock (Table 1).
While these studies examined sepsis in general, the find-
ings are probably applicable to pneumonia which was
the leading source of infection, affecting 1278 out of the
enrolled 4201 patients. Subgroup analysis by site of in-
fection in the ProCESS study did not reveal significant
differences when compared with the full analysis [63]. It
is likely that the data from Rivers et al. [62] pushed clini-
cians towards more aggressive and early resuscitation in
recent years, such that the majority of patients in the
usual care arms of the ProCESS, ARISE, and ProMISe
studies received prompt fluids and vasopressors, even
though central venous pressure and central venous oxy-
genation were not targeted [63–68].
Early respiratory support
Acute respiratory failure frequently complicates severe
CAP; the combined impact of acute respiratory failure
and sepsis on mortality is exponential [69]. Delay in oxy-
genation assessment using pulse oximetry or arterial
blood gas measurements beyond 3 hours from the time
of triage at hospital admission is independently associ-
ated with increased mortality [70].
In the multicentre FLORALI study, 310 patients with
acute hypoxaemic respiratory failure and a ratio of the
partial pressure of arterial oxygen to the fraction of in-
spired oxygen (PaO2/FIO2) ≤ 300 mmHg, but without
haemodynamic instability, were randomised within 3
hours of meeting inclusion criteria to high-flow oxygen
therapy through a nasal cannula, standard oxygen ther-
apy delivered through a face mask, or non-invasive ven-
tilation [71]. There were 197 patients with CAP, 37
patients with hospital-acquired pneumonia, and 20
patients with pneumonia and an immunocompromising
condition. The assigned treatments were commenced a
median time of 60 minutes after randomisation.
Although high-flow nasal cannulae did not reduce intub-
ation rates, ventilator-free days were increased at day 28
and survival was improved at day 90 (Table 1).
However, use of high-flow nasal cannulae and non-
invasive ventilation must not delay endotracheal intub-
ation when needed. Delay in intubation beyond 3 days
from the onset of CAP symptoms has been associated
with increased mortality [72]. Among patients in a
French study who were intubated after failure of non-
invasive ventilation for severe CAP, those with a longer
delay in intubation were more likely to die [73]. A
Korean study showed that delay in intubation after a
failed trial of high-flow nasal cannulae increased mortal-
ity [74]. Criteria to prompt clinicians to intubate may
help prevent such delays. For example, the FLORALI
study advised intubation in the presence of haemo-
dynamic instability, neurological deterioration, or per-
sisting or worsening respiratory failure, as defined by
two or more of the following: respiratory rate > 40
breaths per minute, signs of high respiratory-muscle
workload, copious tracheal secretions, arterial pH < 7.35,
and pulse oximetry reading < 90 % for >5 minutes [71].
Pneumonia is the most common cause of acute re-
spiratory distress syndrome (ARDS) [75], and as detailed
in Table 1 accounts for a large proportion of participants
in multiple ARDS trials. Lung-protective ventilation with
low tidal volumes of 6 ml/kg of predicted body weight
and limitation of the driving pressure (tidal volume di-
vided by respiratory system compliance) after intubation
have been associated with reduced mortality [76, 77]
(Table 1). The impact of limiting tidal volumes on mor-
tality is greatest at the start of mechanical ventilation
[78]. A patient-level meta-analysis of three large multi-
centre randomised trials suggested that higher positive-
end expiratory pressure may improve survival [79],
although subsequent systematic reviews have not found
a similar association [80] (Table 1). Early initiation of a
48-hour infusion of cisatracurium for neuromuscular
blockade for patients with severe hypoxaemia (PaO2/
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FIO2 < 150 mmHg) lowers mortality [81, 82], as does
early prone positioning [83, 84] (Table 1).
Early corticosteroids
While systemic corticosteroids attenuate the inflamma-
tory response in CAP, recent data on their role are con-
flicting. In a multicentre randomised controlled trial of
785 patients, 386 of whom had severe CAP as defined
by PSI classes IV and V, Blum et al. [85] found that
corticosteroids shortened the time to clinical stability. In
another trial of 120 patients with severe CAP and C-
reactive protein levels > 150 mg/L, Torres et al. [86]
found that corticosteroids decreased treatment failure,
although predominantly by halting radiographic progres-
sion rather than improving patient-centric outcomes.
Three recent meta-analyses came to different conclu-
sions, with two analyses suggesting that corticosteroids
decrease mortality in severe CAP [87, 88] (Table 1) and
one analysis finding no impact on mortality [89]. The
latter review, however, suggested that corticosteroids are
safe, and may reduce the risk of ARDS, lengths of hos-
pital and ICU stay, and time to clinical stability. These
meta-analyses are limited by the heterogeneity of the
included studies, and in particular are skewed by an out-
lying randomised trial by Confalonieri et al. [90] which
found that hydrocortisone reduced mortality from 38 %
to 0 %. More data are thus needed before corticosteroids
become routine treatments for severe CAP [91].
Early use of care bundles
Care bundles combine several management practices to
improve outcomes [53]. In 2002, the Surviving Sepsis
Campaign recommended that a resuscitation bundle
should be performed within 6 hours for septic patients
[92]. The bundle included principles from EGDT, in
addition to blood cultures and broad-spectrum antibi-
otics. Recent international analyses by the Surviving
Sepsis Campaign showed that compliance to the guide-
lines was associated with decreased mortality [58, 93].
A few before-and-after studies have focused on sepsis
care bundles derived from the Surviving Sepsis Cam-
paign guidelines [58] for severe CAP. In a single-centre
study in China, Guo et al. [94] defined severe CAP
according to the IDSA/ATS major criteria and applied
the Surviving Sepsis Campaign’s 6-hour resuscitation
bundle (and a 24-hour management bundle) for these
patients. While the intervention was associated with a
decrease in overall hospital mortality from 44 % to 29 %,
full compliance to the bundles was associated with a
greater than twofold decrease. Georges et al. [95] re-
ported that a similar bundle including antibiotic therapy,
fluids, and vasoactive agents was associated with a
decrease in mortality from 43 % to 31 % in patients with
severe CAP as defined by ICU admission in a single
French centre. Hortmann et al. [96] implemented a care
bundle for all patients with CAP in a German ED. The
bundle comprised checklists on history, clinical examin-
ation, investigations including lactate measurement and
blood cultures, risk stratification according to CRB65,
and treatment including antibiotic guidelines and fluid
resuscitation. Hospital mortality decreased from 14 % to
11 %. Sixteen United Kingdom hospital trusts partici-
pated in a quality improvement programme incorporat-
ing a British Thoracic Society care bundle which
included the use of the CURB65 score, standardised
oxygen assessment and prescription, and chest X-ray
scan and targeted antibiotics within 4 hours of hospital
admission [97]. Bundle implementation was associated
with improved 30-day inpatient mortality (Table 1).
Dean et al. [98] showed that four hospital EDs experi-
enced lower CAP mortality after introduction of an elec-
tronic clinical decision support tool compared with
three usual care hospitals. The tool had multiple fea-
tures, including electronic calculation of the IDSA/ATS
minor criteria coupled with logic for ICU admission.
Treatment protocols in the EDs and ICUs guided man-
agement [99].
Early collaboration between teams
Without explicit guidelines, clinical management differs
between individual physicians [100]. Workflows that in-
corporate the interventions reviewed here are needed,
but multiple barriers slow their adoption. Using the
framework drawn by Cabana et al. [101], these barriers in-
clude: a lack of awareness of, familiarity with, or agree-
ment with the workflows, lack of self-efficacy (e.g.
confidence in inserting central venous catheters for vaso-
pressors), disbelief that the workflows can reduce mortal-
ity, inertia, and external barriers such as cumbersome
workflows, insufficient staff, and insufficient time. Over-
coming these barriers requires close liaison between emer-
gency medicine, respiratory medicine, and critical care
medicine clinicians, as well as clinical decision support
tools. These are unfortunately not emphasised in current
guidelines for CAP and sepsis [14–17].
To illustrate, Lim et al.’s intervention [27] was de-
signed and sustained by the same multidisciplinary team
over 7 years, comprising representatives from the ED
and the respiratory and critical care medicine depart-
ment. Local champions trained nurses and physicians on
the definitions and management of severe CAP. Orienta-
tion tutorials were provided for new staff, and posters
and forms were displayed prominently. Data on compli-
ance were reviewed every 2–4 weeks during business
meetings and email discussions, and regular feedback
was obtained to improve the workflow. These processes
continue to this day. Guo et al. [94] used a personal
pocket information card as a daily reminder of the steps
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required for severe CAP, and provided weekly feedback
to staff on compliance to their workflow through group
discussions and posters. Dean et al. [98] not only de-
ployed their electronic pneumonia clinical decision sup-
port tool, but also closely followed the principles of
change management.
The first 24 hours
We propose in Fig. 1 a bundled approach to early and
aggressive treatment to improve survival for patients
with severe CAP. The algorithm is guided by clinical
decision support tools available in the ED in paper or
electronic form [27, 94, 98]. The approach relies on ED
nurses to rapidly diagnose CAP at triage, and then sus-
pect sepsis using the qSOFA score by identifying low
blood pressure, tachypnoea, and altered mental state
[32]. It empowers the nurses to order lactate measure-
ments, blood cultures, and chest X-ray scans, to insert
large-bore intravenous cannulae, and to alert the emer-
gency physicians [27]. Broad-spectrum antibiotics must
be given early, and include a beta-lactamase-stable beta-
lactam and a macrolide [14–17, 39, 48, 56]. Patients with
hypotension and/or elevated lactate are given boluses of
crystalloids [32, 58]. Severe CAP is defined by the need
for intubation and/or vasopressors, or by more subtle
features such as the IDSA/ATS minor criteria [14].
RECOGNISE SEPSIS:
At risk of deterioration
2 of the following: :
Systolic blood pressure 100 mm Hg
Respiratory rate 22/min
Altered mental state or confusion
RECOGNISE SEVERE CAP:
Needs intubation and/or vasopressors
3 of the following:
30/min
PaO2/FIO2 250 mm Hg
Multilobar infiltrates
Altered mental state or confusion
20 mg/dL
White blood cell count 4,000 cells/mm3
Platelet count 100,000 cells/mm3
Core temperature 36.0°C
Mean blood pressure 65 mm Hg
HAEMODYNAMIC SUPPORT:
Intravenous crystalloid 30 mL/kg fast
Repeat 500 mL fluid boluses










Measure complete blood count
Measure urea and electrolytes
Perform blood cultures
Perform chest X-ray
Insert large bore cannulae
Inform physician




RECOGNISE POSSIBLE SEPTIC SHOCK:
Systolic blood pressure 90 mm Hg or
Mean blood pressure 65 mm Hg
Lactate 2 mmol/L
RESPIRATORY SUPPORT:
Consider high flow nasal cannula
if predominantly hypoxaemic respiratory failure
Consider intubatiion 
If multi-organ failure 
CALL RESPIRATORY AND CRITICAL CARE MEDICINE TEAM:
Consider ICU admission if not better
ANTIBIOTICS:
Follow local guidelines




if still hypotensive and not fluid responsive
ARDS:
Low tidal volume and plateau pressure
Low driving pressure
Consider neuromuscular blockade 
and prone positioning
if PaO2/FIO2 150 mm Hg
Fig. 1 Suggested approach to early and aggressive management measures for severe community-acquired pneumonia (CAP). ED emergency
department, PaO2 partial pressure of arterial oxygen, FIO2 fraction of inspired oxygen
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High-flow nasal cannulae may be considered for respira-
tory failure [71], but the application of stringent semi-
elective intubation criteria is preferred to emergent
intubation near the point of cardiorespiratory arrest
[71–73]. The respiratory and critical care medicine
department(s) should be engaged early. Patients who do
not improve with initial management measures should
be managed in the ICU [27, 98, 102], where norepineph-
rine may be infused for septic shock [103] and lung-
protective ventilation with low tidal volumes and driving
pressures is provided for ARDS. Prone positioning and/
or neuromuscular blockade may be needed for moderate
to severe cases [76, 77, 79, 81, 83].
The proposed approach has its limitations and must
be adapted to each individual setting. Selected antimi-
crobials should be tailored to the local antibiogram.
While we have focused on antibiotics for bacterial path-
ogens, empiric treatment with neuraminidase inhibitors
for influenza in the presence of typical symptoms should
be considered [14, 104]. Resource-limited settings may
not be able to measure lactate levels, and more work is
needed to evaluate the clinical utility of the qSOFA score
[32]. The IDSA/ATS minor criteria are featured because
they are well recognised, validated, and easy to use, but
no severity assessment tool has perfect sensitivity or
specificity [5, 6, 105] so the physicians’ clinical judgment
remains key. Importantly, the workflow is highly
dependent on a seamless working relationship between
nurses and doctors, and between ED and respiratory and
critical care medicine teams.
Conclusions
Severe CAP has claimed too many lives for too long.
The emergency medicine and respiratory and critical
care medicine communities should work together to
decrease mortality by implementing early and aggressive
management measures upon recognition of severe CAP.
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